Vijayaraj Kumar Palanirajan

Dr. Vijayaraj Kumar Palanirajan

UCSI University, Kuala Lumpur, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2008 in Chemical Reviews
Verified
Journal Article
Closed access
RTRakesh Kumar Tekade
Rakesh Kumar Tekade
Vijayaraj Kumar PalanirajanVijayaraj Kumar Palanirajan
Vijayaraj Kumar Palanirajan
NJNarendra Kumar Jain
Narendra Kumar Jain

1 January 2006 in Journal of Drug Targeting
Verified
Journal Article
Closed access
Vijayaraj Kumar PalanirajanVijayaraj Kumar Palanirajan
Vijayaraj Kumar Palanirajan
AAAbhay Asthana
Abhay Asthana
TDTathagata Dutta
Tathagata Dutta
NJNarendra K. Jain
Narendra K. Jain
The present study was aimed at developing and exploring the use of mannosylated dendritic architecture for the selective delivery of an anti-tuberculosis drug, rifampicin (RIF) to alveolar macrophages (AM). The mannosylated dendritic architecture was synthesized and characterized by using IR and NMR spectroscopy. RIF was efficiently loaded into mannosylated dendrimer using dissolution method. Various physicochemical and physiological parameters such as UV, SEM, DSC, drug loading, solubilization, pH dependent in-vitro release, hemolytic toxicity, phagocytic AM uptake and cytotoxicity concerning the mannosylated dendrimer were evaluated. RIF loaded mannosylated dendrimer reduced release rate of drug in pH 7.4, hemolytic toxicity and cytotoxicity; whereas enhanced drug release in pH 5.0 and AM uptake was observed. The present novel dendritic system displayed suitability in terms of biocompatibility and site-specific delivery of antitubercular drug RIF.

1 January 2006 in Critical Reviews™ in Therapeutic Drug Carrier Systems
Verified
Journal Article
Closed access
MNManoj Nahar
Manoj Nahar
TDTathagata Dutta
Tathagata Dutta
SMSenthilkumar Murugesan
Senthilkumar Murugesan
AAAbhay Asthana
Abhay Asthana
DMDinesh Kumar Mishra
Dinesh Kumar Mishra
NJNarendra Kumar Jain
Narendra Kumar Jain
Nanotechnology is a multidisciplinary field and has achieved breakthroughs in bioengineering, molecular biology, diagnostics, and therapeutics. A recent advance in nanotechnology is the development of a functional nanosystem by incorporation, adsorption, or covalent coupling of polymers, carbohydrates, endogenous substances/ligands, peptides, proteins, nucleic acids, and polysaccharides to the surface of nanoparticles. Functionalization confers a wide array of interesting properties such as stealth characteristics, a bioadhesive property, and that it prevents aggregation of nanoparticles, imparts biostability and solubility, reduces toxicity, and provides site-specific delivery. This makes the nanosystem an intelligent tool for diagnostics, prognostics, and controlled and sustained delivery of protein, peptide, pDNA, and other therapeutic agents to specific targets (tissue, cell, and intracellular). Various types of functional nanosystems, such as carbon nanotubes, quantum dots, polymeric micelles, dendrimers, metallic nanoparticles, and liposomes, are being extensively explored. However, high tissue accumulation of nonbiodegradable nanoparticles has caused toxicity problems and rendered them as not-so-popular therapeutic and diagnostic systems. The toxicity and safety of nonbiodegradable nanoparticles are subject to future research. Polymeric nanoparticles have offered attractive alternative modules due to biocompatibility, nonimmunogenicity, nontoxicity, biodegradability, simple preparation methods, high physical stability, possibility of sustained drug release, and higher probability for surface functionalization. Depending on properties that have been modified, polymeric nanoparticles can be grouped in to four classes, namely, stealth, polysaccharide decorated biomimetic, bioadhesive, and ligand-anchored functional polymeric nanoparticles (f-PNPs). This review explores the ligand-anchored f-PNP as a carrier for active delivery of bioactives, envisaged to date. This review also details the ligands available for conjugation, their method of coupling to nanoparticles, and applications of f-PNPs in anticancer drug delivery, oral delivery, gene delivery, vaccine delivery, and intracellular delivery; site-specific delivery to liver, macrophages, lymphatics, and brain; and miscellaneous applications. This review also addresses formidable challenges encountered, and proposes some future strategies for development of a promising site-specific active delivery system.

1 February 2007 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
VGVirendra Gajbhiye
Virendra Gajbhiye
Vijayaraj Kumar PalanirajanVijayaraj Kumar Palanirajan
Vijayaraj Kumar Palanirajan
RTRakesh Kumar Tekade
Rakesh Kumar Tekade
NJN. Jain
N. Jain

1 March 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VGVirendra Gajbhiye
Virendra Gajbhiye
Vijayaraj Kumar PalanirajanVijayaraj Kumar Palanirajan
Vijayaraj Kumar Palanirajan
RTRakesh Kumar Tekade
Rakesh Kumar Tekade
NJN.K. Jain
N.K. Jain

1 January 2007 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
Vijayaraj Kumar PalanirajanVijayaraj Kumar Palanirajan
Vijayaraj Kumar Palanirajan
HAHrushikesh Agashe
Hrushikesh Agashe
TDTathagata Dutta
Tathagata Dutta
NJNarendra K. Jain
Narendra K. Jain
The present study was aimed at developing and exploring the use of PEGylated poly (propylene imine) dendritic architecture for the delivery of an anti-tuberculosis drug, rifampicin. For this study, PEGylated poly(propylene imine) dendritic architecture was synthesized and loaded with rifampicin. Various physicochemical and physiological parameters UV, IR, NMR, TEM, DSC, drug entrapment, drug release and hemolytic toxicity of both PEGylated and non- PEGylated systems were determined and compared. The PEGylation of the systems was found to have increased their drug-loading capacity, reduced their drug release rate and hemolytic toxicity. The systems were found suitable for prolonged delivery of rifampicin.